Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9DHNZ)

Drug Name

Cyclopentyl-(9-methyl-9H-purin-6-yl)-amine Drug Info

Synonyms

N6-Cyclopentyl-9-methyladenine; N(6)-Cyclopentyl-9-methyladenine; N-0840; n-cyclopentyl-9-methyl-9h-purin-6-amine; CHEMBL48278; 109292-91-3; Lopac-N-154; 9H-Purin-6-amine,N-cyclopentyl-9-methyl-; AC1Q4XZM; Cyclopentyl-(9-methyl-9H-purin-6-yl)-amine; Lopac0_000921; ZINC5203; SCHEMBL1322040; AC1L1I31; DTXSID60148871; LZMRVYPPUVMKOI-UHFFFAOYSA-N; N6 -Cyclopentyl-9-Methyl Adenine; N-cyclopentyl-9-methylpurin-6-amine; n0840; BDBM50009698; CCG-205003; NCGC00094232-01; NCGC00015717-03; NCGC00094232-03; NCGC00015717-02; NCGC00015717-01

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 4401
CAS Number: CAS 109292-91-3
TTD Drug ID: DM9DHNZ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Adenosine A1 receptor (ADORA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caffeine	DMKBJWP	Allergic rhinitis	CA08.0	Approved	[2]
Rolofylline	DMSZPR3	Heart failure	BD10-BD13	Phase 3	[3]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[4]
AMP-579	DMJ4GPR	Hyperlipidaemia	5C80	Phase 2	[5]
SELODENOSON	DMQM3IX	Cardiac arrhythmias	BC9Z	Phase 2	[6]
Apaxifylline	DMQMV9F	Cognitive impairment	6D71	Phase 2	[7]
SLV320	DM867BJ	Heart failure	BD10-BD13	Phase 2	[8]
DTI-0009	DMV84OK	Atrial fibrillation	BC81.3	Phase 2	[6]
Capadenoson	DMYWO62	Atrial fibrillation	BC81.3	Phase 2	[9]
BAY 1067197	DM4JGNH	Heart failure	BD10-BD13	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A1 receptor (ADORA1)	TTK25J1	AA1R_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82.
2	Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
3	Association between the PDE4D gene and ischaemic stroke in the Chinese Han population. Clin Sci (Lond). 2009 Aug 17;117(7):265-72.
4	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
5	Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
6	Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308.
7	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004779)
8	Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart. Clin Sci (Lond). 2009 Jul 16;117(4):157-64.
9	A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10.
10	Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Current Issue vol. 111 no. 12 Celine Valant, 4614-4619.